Auxogyn has introduced its new non-invasive early embryo viability assessment (Eeva) test in the European Union.
The test uses the intelligent computer vision software to measure clinically validated cell-division parameters from video images and provide clinicians and patients with objective information to more confidently select embryos for transfer.
The company said Eeva also predicts with high accuracy at the cleavage stage, where embryos likely grow to the blastocyst stage, a critical stage in embryo development.
The company has installed Eeva test at Hewitt Fertility Center in Liverpool, UK to predict embryo viability.
The results from a prospective, multi-center, 160-patient clinical trial demonstrated that Eeva was able to predict blastocyst formation at the cleavage stage with 85% specificity, reducing the false positive rate from 43% to 15% compared with traditional morphology selection.
Eeva also demonstrated the ability to track and analyze cell division timings with greater than 90% accuracy and was able to increase the consistency of embryo assessment across embryologists.
Hewitt Fertility Center lead consultant and Liverpool Women’s National Health Service Hospital Foundation Trust consultant gynaecologist Charles Kingsland said, "By using Eeva, we will be able to help our patients make more informed personal decisions and provide them with the best care possible."